Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
22.47
-0.40 (-1.75%)
Dec 20, 2024, 4:00 PM EST - Market closed
Enliven Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 100.62 | 100.14 | 75.54 | 110.02 | 130.37 |
Short-Term Investments | 191.21 | 153.01 | - | - | - |
Cash & Short-Term Investments | 291.83 | 253.15 | 75.54 | 110.02 | 130.37 |
Cash Growth | 10.76% | 235.14% | -31.35% | -15.60% | - |
Prepaid Expenses | 5.11 | 2.95 | 2.22 | 0.65 | 0.06 |
Restricted Cash | 0.05 | 0.05 | - | - | 0.05 |
Other Current Assets | - | 10 | - | - | 0.1 |
Total Current Assets | 297 | 266.15 | 77.75 | 110.67 | 130.59 |
Property, Plant & Equipment | 0.63 | 1.06 | 1.52 | 0.95 | 0.42 |
Long-Term Deferred Charges | 0.56 | 0.56 | 3.98 | 1.65 | - |
Other Long-Term Assets | 7.24 | 4.09 | 0.05 | 0.05 | - |
Total Assets | 305.43 | 271.87 | 83.3 | 113.33 | 131 |
Accounts Payable | 1.02 | 0.53 | 3.44 | 2.52 | 0.81 |
Accrued Expenses | 15.71 | 14.66 | 4.32 | 2.84 | 0.43 |
Current Portion of Leases | 0.09 | 0.34 | 0.32 | 0.16 | 0.11 |
Other Current Liabilities | 0.22 | 10.36 | 1.64 | 0.23 | 0.14 |
Total Current Liabilities | 17.03 | 25.89 | 9.72 | 5.75 | 1.48 |
Long-Term Leases | - | - | 0.28 | - | - |
Other Long-Term Liabilities | - | 0.07 | 0.38 | 0.71 | 0.08 |
Total Liabilities | 17.03 | 25.96 | 10.37 | 6.47 | 1.56 |
Common Stock | 0.05 | 0.04 | 0 | 0 | 0 |
Additional Paid-In Capital | 508.41 | 400.17 | 6.04 | 2.31 | 0.16 |
Retained Earnings | -220.29 | -154.45 | -82.86 | -45.2 | -20.46 |
Comprehensive Income & Other | 0.24 | 0.14 | - | - | - |
Total Common Equity | 288.4 | 245.91 | -76.83 | -42.89 | -20.3 |
Shareholders' Equity | 288.4 | 245.91 | 72.92 | 106.86 | 129.45 |
Total Liabilities & Equity | 305.43 | 271.87 | 83.3 | 113.33 | 131 |
Total Debt | 0.09 | 0.34 | 0.6 | 0.16 | 0.11 |
Net Cash (Debt) | 291.75 | 252.81 | 74.94 | 109.87 | 130.26 |
Net Cash Growth | 10.87% | 237.37% | -31.79% | -15.66% | - |
Net Cash Per Share | 6.50 | 7.11 | 23.99 | 14.06 | 26.12 |
Filing Date Shares Outstanding | 48.86 | 41.35 | 12.1 | 11.64 | 4.99 |
Total Common Shares Outstanding | 47.25 | 41.29 | 12.1 | 11.64 | 4.99 |
Working Capital | 279.97 | 240.26 | 68.04 | 104.92 | 129.11 |
Book Value Per Share | 6.10 | 5.96 | -6.35 | -3.68 | -4.07 |
Tangible Book Value | 288.4 | 245.91 | -76.83 | -42.89 | -20.3 |
Tangible Book Value Per Share | 6.10 | 5.96 | -6.35 | -3.68 | -4.07 |
Machinery | 1.46 | 1.41 | 1.26 | 0.65 | 0.46 |
Source: S&P Capital IQ. Standard template. Financial Sources.